Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BTAI BioXcel Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BTAI
Price (delayed)
$1.53
Market cap
$8.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$23.51
Enterprise value
$81.11M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
Highlights
BTAI's EPS has surged by 76% year-on-year and by 32% since the previous quarter
BioXcel Therapeutics's net income has surged by 67% YoY and by 16% QoQ
The gross profit has plunged by 51% from the previous quarter but it has grown by 2.5% YoY
The equity has dropped by 65% year-on-year and by 9% since the previous quarter
BTAI's gross margin has dropped by 51% since the previous quarter and by 38% year-on-year
Key stats
What are the main financial stats of BTAI
Market
Valuations
Earnings
Shares outstanding
5.49M
Market cap
$8.39M
Enterprise value
$81.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.8
Revenue
$2.27M
Gross profit
$123,000
Operating income
-$67.25M
Net income
-$59.6M
EBIT
-$44.47M
EBITDA
-$44.16M
Free cash flow
-$72.03M
Per share
Balance sheet
Liquidity
EPS
-$23.51
EPS diluted
-$23.51
Free cash flow per share
-$28.41
Book value per share
-$34.85
Revenue per share
$0.89
TBVPS
$15.12
Total assets
$38.34M
Total liabilities
$131.44M
Debt
$102.57M
Equity
-$93.1M
Working capital
$15.16M
Debt to equity
-1.1
Current ratio
1.68
Quick ratio
1.35
Net debt/EBITDA
-1.65
Margins
Efficiency
Dividend
EBITDA margin
-1,948.9%
Gross margin
5.4%
Net margin
-2,630.1%
Operating margin
-2,967.6%
Return on assets
-101.5%
Return on equity
N/A
Return on invested capital
-52.3%
Return on capital employed
-276.1%
Return on sales
-1,962.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BTAI stock price
How has the BioXcel Therapeutics stock price performed over time
Intraday
-3.16%
1 week
-14.04%
1 month
-14.53%
1 year
-95.85%
YTD
-74.41%
QTD
-24.63%
Financial performance
How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$2.27M
Gross profit
$123,000
Operating income
-$67.25M
Net income
-$59.6M
Gross margin
5.4%
Net margin
-2,630.1%
BTAI's net margin has surged by 80% year-on-year and by 16% since the previous quarter
BTAI's operating margin has soared by 76% YoY and by 12% QoQ
BioXcel Therapeutics's net income has surged by 67% YoY and by 16% QoQ
BTAI's revenue has surged by 64% year-on-year
Price vs fundamentals
How does BTAI's price correlate with its fundamentals
Growth
What is BioXcel Therapeutics's growth rate over time
Valuation
What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.8
BTAI's EPS has surged by 76% year-on-year and by 32% since the previous quarter
The equity has dropped by 65% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 92% lower than the last 4 quarters average of 22.3
BTAI's revenue has surged by 64% year-on-year
Efficiency
How efficient is BioXcel Therapeutics business performance
BTAI's return on sales has surged by 84% year-on-year and by 21% since the previous quarter
BioXcel Therapeutics's ROIC has soared by 76% YoY and by 23% from the previous quarter
BioXcel Therapeutics's return on assets has increased by 30% YoY and by 3.3% QoQ
Dividends
What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BTAI.
Financial health
How did BioXcel Therapeutics financials performed over time
The total assets is 71% less than the total liabilities
The total assets has contracted by 48% YoY and by 22% from the previous quarter
BTAI's quick ratio is down by 44% year-on-year and by 15% since the previous quarter
The equity has dropped by 65% year-on-year and by 9% since the previous quarter
BioXcel Therapeutics's debt to equity has increased by 39% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.